Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up Novartis (NYSE: NVS) and Roche (NASDAQOTH: RHHBY).
However, Pfizer appears likely to lose its No. 1 spot among drugmakers. According to research firm EvaluatePharma, Novartis should push Pfizer out of the top position by 2022. Should Pfizer shareholders be concerned? Not at all. Here's why it doesn't matter.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€26.52
0.110%
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 40 € shows a very positive potential of 50.83% compared to the current price of 26.52 € for Pfizer Inc..
